SOURCE: Paragon Financial Limited

Paragon Financial Limited

December 08, 2011 08:16 ET

Cel-Sci and Zalicus Make Headway in Recession Proof Biotech Sector

The Paragon Report Provides Equity Research on Cel-Sci & Zalicus

NEW YORK, NY--(Marketwire - Dec 8, 2011) - The Biotechnology industry has long been regarded as a "Recession Proof" sector of the economy. Even during periods of financial turmoil, most people will continue purchasing their medication. Studies show the number of new drugs being developed is growing at a rapid clip, while the number of small biotech firms continues to increase. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cel-Sci Corporation (NYSE Amex: CVM) and Zalicus, Inc. (NASDAQ: ZLCS). Access to the full company reports can be found at:

www.paragonreport.com/CVM

www.paragonreport.com/ZLCS

While Big Pharma continues to shed jobs due to consolidation in the space, smaller biotech firms are showing signs of growth. According to a recent article from Genetic Engineering and Biotechnology News, the most recently available figures by Battelle show that US biotech employment inched up 0.2% during the period between 2007 and 2009, to about 1.36 million jobs. The number of bioscience establishments climbed between '08 and '09 from 47,593 to 48,059, the article finds.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system. The company recently provided an update on its Phase III clinical trial of Multikine (Leukocyte Interleukin, Injection), which is currently being investigated in an open-label, randomized, controlled, multi-center study. "We are pleased by the progress we have made in moving this study forward. Having brought on-line 35 clinical centers in 8 countries on 3 continents in less than one year took great effort," said Geert Kersten, CEL-SCI's Chief Executive Officer.

Earlier this month Zalicus announced the initiation of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160 (formerly NMED-160), a novel oral N-type calcium channel blocker. Zalicus applies its selective ion channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer